დასაწყისი · კატალოგი · პროფილი · ცხრილი
სკრინინგი BODY HANDBOOK
სკრინინგი · §143
Skin Self-Examination
Once a month, in front of the bathroom mirror with a hand mirror in the other hand, you spend six minutes learning your own skin. The dream isn't dramatic — it's the version of you whose worst skin-cancer story is a thin white scar from a six-minute outpatient excision, instead of the version who finds out four years late that a spot on the back of a shoulder is now a stage IV diagnosis. A 0.5 mm melanoma caught early carries roughly a 99% five-year survival; a 4 mm one carries about 75%; once it has spread, well under 30%. The whole intervention is a mirror, a hand mirror, and a phone for photos.
გააკეთე · ყოველწლიურად მტკიცებულება განვითარებადი თავი სკრინინგი

The catch is everything. Skin cancer caught at a millimetre is an outpatient excision and a small scar; caught at four millimetres or after spread, it's a different disease — and the difference is decided by whether you looked at the back of your own shoulder this autumn or didn't. The cost is six minutes a month and a hand mirror. The cost of skipping is asymmetric in the way that matters: most readers will never need it, the one in thirty-three white Americans who develops a melanoma over a lifetime will be very glad they did, and the warning signs of basal-cell and squamous-cell skin cancer travel in the same six minutes. It's a chore, honestly — but a cheap one, and the kind whose worst-case absence is catastrophic.

Skin cancer is unusual among cancers in that it grows on the outside of you. Most melanomas spend months to years in a flat, surface-level phase — visible, findable, biopsiable — before they begin growing downward into the skin. The depth they reach before excision is what mostly decides survival: a melanoma less than a millimetre thick carries a five-year melanoma-specific survival of around 99%; one over four millimetres, around 75%; once it has spread to distant organs, well under 30% Gershenwald et al. 2017. Months of patient delay convert directly into millimetres of depth, and millimetres of depth convert into outcomes that diverge by an order of magnitude. The job of self-examination is to compress that delay — to notice the new or changing lesion in weeks instead of years.

Two pattern-recognition tools do most of the work. The first is ABCDE, a checklist for any mole or pigmented spot. Asymmetry: one half doesn't match the other. Border: edges are ragged, blurred, or notched, not smooth. Color: more than one shade — brown, black, sometimes red, white, or blue — in the same spot. Diameter: larger than about six millimetres, the size of a pencil eraser, though some melanomas are smaller. Evolving: any change at all in size, shape, colour, or symptoms over weeks to months. Of the five, Evolution and Diameter discriminate hardest; about eight or nine in ten melanomas show at least one ABCDE feature when the rule is applied as a whole Tsao et al. 2015.

The second is the ugly duckling sign — a separate principle, easier to apply once you've inventoried your own skin. Your moles tend to look like each other: same general size, same colour family, same shape. The one that looks unlike the others — the outlier in a crowd that otherwise rhymes — is statistically more likely to be melanoma than the lesion that merely looks atypical in isolation Grob & Bonerandi 1998. When trained dermatologists used this comparative method on photographs of patients' full mole maps, specificity rose from 0.88 to 0.96 and the number of lesions flagged for biopsy fell by roughly a factor of seven, without missing melanomas Gaudy-Marqueste et al. 2017. You're doing the same thing, on the same skin, with more visits than any dermatologist will ever have.

Basal-cell and squamous-cell carcinomas — the much commoner, much less deadly skin cancers — have their own signatures, and they live mostly on chronically sun-exposed sites: face, ears, neck, scalp, the backs of hands, the front of the shins. A pearly or translucent papule with tiny visible blood vessels running across it is the classic basal-cell. A sore that bleeds, scabs, heals partway, and then opens again — or never heals at all — over a couple of months is another. A rough, scaly, persistent red patch on sun-damaged skin, or a wart-like growth that crusts and bleeds, points at squamous-cell. None of these reliably hurt or itch. The catch is the same as for melanoma: change, persistence, and a thing that wasn't there before.

The biology says yes: catch melanoma at one millimetre and people live; catch it at four millimetres and many don't. The screening evidence is messier. The cleanest direct study is a population-based case-control by Berwick and colleagues at Yale, who interviewed Connecticut melanoma patients and matched controls about whether they had performed careful, deliberate skin self-examination. People who said yes had roughly a two-thirds lower risk of dying from melanoma than people who said no Berwick et al. 1996; long-term follow-up of the same cohort showed the survival gap held seventeen years later Paddock et al. 2016. In a separate analysis, people who examined their own skin caught their own melanoma at roughly twice the rate of people who didn't, and the tumours they caught were thinner at excision Pollitt et al. 2009.

Honest about the gap: none of these trials proved fewer people die. Proving it would take tens of thousands of participants followed for a decade, and no one has run that study. The US Preventive Services Task Force has reviewed the evidence repeatedly — most recently in 2023 — and concludes there isn't enough to recommend for or against, an I rating USPSTF 2023. The American Academy of Dermatology and the American Cancer Society read the same literature and recommend the practice anyway, on the grounds that the biology is tight and the cost is six minutes AAD 2024. Both positions are reasonable. The framing this entry takes is: the mortality benefit is more likely real than not, the magnitude is uncertain, and the intervention is cheap enough that the asymmetry favours doing it — particularly for the subset of readers in whom melanoma risk is materially elevated.

If you don't

The forecast scales with how the disease is biologically structured. A melanoma is millimetres thick when it is found, and millimetres of thickness are what the body's prognosis pays attention to. The reader who looks once a month finds the new dark spot on their shoulder in November; it's a half-millimetre deep when the dermatologist looks at it in December; it comes off in an outpatient visit in January under a local anaesthetic, leaving a thin scar a few centimetres long, and the reader's chance of dying from this melanoma is around one in a hundred Gershenwald et al. 2017.

The reader who doesn't look — who has the same dark spot, but doesn't know it's there until it begins to itch in April or bleed in June — meets the same dermatologist with a different problem. A two-and-a-half-millimetre melanoma takes more skin, takes a sentinel-lymph-node biopsy under general anaesthesia, and starts the conversation about adjuvant treatment. Five-year survival sits at three in four. Catch it later still, after it has spread to a lymph node or to the lung, and survival falls below one in three even in the era of modern checkpoint-inhibitor therapy. The clinical biology converts months of inattention into millimetres of depth, and millimetres of depth into outcomes that diverge by an order of magnitude.

Most readers will live their entire life without a melanoma to catch, and won't notice the absence of an event. The reader whose number does come up — about one in thirty-three white Americans over a lifetime, lower in other groups, but skewed sharply higher in the high-risk subset who can identify themselves — sees a future shaped by which month they were paying attention. For non-melanoma skin cancers the stakes are different and more cosmetic: a basal-cell carcinoma caught small on the side of the nose comes off cleanly with a few sutures; one neglected for three years requires Mohs micrographic surgery, an hour of reconstruction, and leaves a face the reader has to negotiate with for the rest of their life.

The day-to-day of doing the exam is uneventful. The day-to-day of not doing it is also uneventful, almost always. The difference shows up only in the one month, the one year, the one decade in which a small lesion would have crossed from radial growth into vertical growth, and the reader looking at themselves in the mirror catches it on the early side of that line.

How to do it

Strip down in a well-lit room. You need a full-length mirror you can stand in front of, a hand mirror, and your phone for photos. Plan on five to ten minutes — longer the first time, because you're inventorying things you've never deliberately looked at before. Pick a fixed day each month so it actually happens: the first of the month, your partner's birthday, the day rent comes due. Skin self-examination is the kind of habit that quietly evaporates if it isn't anchored to something.

Two upgrades worth knowing. First, the partner check — your partner inspects your back, scalp, and posterior thighs; you do the same for them. These are the sites where men's melanomas concentrate and where self-examination alone has the largest blind spot. The American Academy of Dermatology explicitly recommends this as part of the practice AAD 2024. Second, if you carry serious melanoma risk — more than a hundred moles, several atypical-looking ones, a personal history of skin cancer, a first-degree relative with melanoma, an organ transplant, a history of indoor tanning before age thirty-five — ask your dermatologist about total-body photography. It is a one-time baseline imaging session (some clinics now use 3D capture) that gives you and your dermatologist a frozen reference for what your moles looked like, and which one is new.

Where to look, depending on you

The map shifts with skin tone, with sex, and with what your moles look like. If you have fair skin, freckle easily, burned in your teens, or carry red or blonde hair — Fitzpatrick I or II — your lifetime cutaneous melanoma risk in the US is roughly three percent, about one in thirty-three SEER 2024. Men tend to develop melanoma on the back and trunk, women on the legs. If you have a hundred or more moles, several that look unusual, a personal or family history of melanoma, organ transplant, a CDKN2A mutation, or a history of tanning beds, you're in a substantially elevated band where structured monthly self-exam plus annual dermatology screening is the standard of care, not a discretionary choice.

For darker skin tones — Black, Asian, Hispanic, South Asian — cutaneous melanoma is much less common, but when it occurs it disproportionately appears on the parts of the body that the sun-exposure map ignores: the palms of the hands, the soles of the feet, and the nail beds. This subtype (called acral lentiginous melanoma) accounts for over half of melanomas in people of African, Asian, and Hispanic descent — versus a few percent in white populations — and it tends to be diagnosed later, with worse outcomes, in part because both patients and primary-care doctors don't look at those sites. Specifically check:

  • The soles of the feet, including the heel and the arch.
  • The palms of the hands.
  • The skin between the toes and fingers.
  • The nail beds — particularly any new dark line running lengthwise that is wider than about five millimetres, or that extends onto the skin around the nail (the cuticle fold).

The same ABCDE thinking applies, with an alternative checklist sometimes added for acral lesions: a Coloured lesion, Uncertain diagnosis, Bleeding, Enlarging, or Delayed healing. The pattern is the same — change and persistence.

What the ABCDE rule misses

ABCDE is the public-education distillation, not the dermatology textbook. It catches the obvious cases — and the typical melanoma is, fortunately, an obvious case — but two genuine subtypes slip through it and are worth naming.

The first is nodular melanoma, which makes up roughly one in seven cutaneous melanomas. Nodular melanomas grow vertically and quickly. They are often perfectly round, perfectly symmetric, uniform in colour, and well-circumscribed at the edge — the opposite of an ABCDE classic. They may also be smaller than the six-millimetre diameter line. They tend to be raised, firm to the touch, and to grow visibly month over month; many bleed when knocked. The pattern to learn alongside ABCDE is EFG: Elevated, Firm, Growing. If a small bump is doing all three, get it looked at, even if it doesn't break any ABCDE rule Tsao et al. 2015.

The second is amelanotic melanoma — a melanoma without pigment. Pink, red, flesh-coloured, or skin-toned, it fails the "Colour" criterion entirely. The cue here is not colour but persistence and asymmetry: a pink papule that grew, that bleeds easily, that hasn't healed in eight weeks. Skin of colour deals with the same problem from a different direction: subungual and acral lesions can be very subtly pigmented, and the dangerous lines are easy to mistake for bruise, fungus, or trauma.

A few other lay assumptions worth correcting:

  • Most skin cancers don't hurt. Waiting until something is painful or itchy lets the lesion grow for months. The structured monthly look is what catches the asymptomatic case.
  • Sunscreen and shade are sun protection — they aren't screening. You can do everything right on UV exposure and still develop melanoma, particularly the acral subtype that isn't UV-driven at all.
  • "Monthly on the dot" isn't magic. The signal in the literature is for regular, structured, not a specific calendar day. Once a month is the common recommendation; every six to eight weeks is fine if it's actually happening.

Where this goes wrong

Self-examination fails in two main ways, both predictable, both fixable.

The geography problem. People consistently miss the scalp, the upper back, the buttocks, the backs of the thighs, the soles, the spaces between the toes, and the nail beds — which is exactly the catalogue of sites where the cancers you most need to catch concentrate. Men's melanomas live on the back; acral melanomas live on soles and nailbeds; basal-cell cancers love the scalp under the hairline. The hand mirror is the cheap fix for the back. A partner who can spend ninety seconds inspecting your scalp is the cheap fix for the part where the hand mirror isn't enough.

The memory problem. "Is this new?" and "Is this changing?" both depend on a reference point. Human memory of what a mole looked like six months ago is poor — and "Evolution" is the most discriminating of the ABCDE criteria, so losing it gives up most of the rule's power. Smartphones solve this for free: a dated, well-lit, scale-included photo of every lesion you've decided to monitor turns recall into comparison. When in doubt, retake the photo with the same framing and look at the two side by side.

Two other failure modes are worth flagging. The first is over-escalation: a self-examiner who books a dermatology biopsy for every benign mole contributes to a separate problem, which is that the rate of melanoma diagnosis in the US has roughly quintupled since 1975 while the death rate has barely moved. Most of that growth is from very thin, in-situ lesions that may never have caused harm Adamson et al. 2024. The escalation threshold worth using is not any spot that exists — it is new, growing, or visually unlike your other moles for more than about a month. The second is the opposite failure: spotting a clearly changing lesion and waiting to see if it goes away. It won't. Persistent change for two months without resolution is the threshold to book the appointment, not the threshold to keep watching.

Related, worth knowing about separately:

  • Sun protection and UV exposure — sunscreen, sun-protective clothing, the dose-response of UV damage. The upstream side of the same problem.
  • Tanning beds — a substantial preventable melanoma risk factor, especially before age thirty-five.
  • Vitamin D from sunlight — the trade-off on the other side of the same UV question.
  • Dermatology screening cadence — when and how often to see a dermatologist for a full skin exam, depending on your risk band.
  • Smartphone skin-check apps — useful as a second opinion on a single lesion; the better-studied ones are reaching dermatologist-level sensitivity on invasive melanoma, but specificity is still uneven and they are not yet a replacement for the structured monthly look.
·
143